For the nine months ended in the fiscal year ending December 2026, revenue was 27,742 million yen (increase YoY), core operating profit was 9,818 million yen, operating profit was 3,175 million yen, and quarterly profit was 2,328 million yen. Full-year guidance is revenue of 33,800\u201348,800 million yen, core operating profit of 7,800\u201322,800 million yen, and operating profit of 700\u201315,700 million yen. Progress made on important license agreements and milestone income, supporting business expansion.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nxera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4565-20261030-01.pdf","jir_short_summary":"For the nine months ended in the fiscal year ending December 2026, revenue was 27,742 million yen (increase YoY), core operating profit was 9,818 million yen, operating profit was 3,175 million yen, and quarterly profit was 2,328 million yen. Full-year guidance is revenue of 33,800\u201348,800 million yen, core operating profit of 7,800\u201322,800 million yen, and operating profit of 700\u201315,700 million yen. Progress made on important license agreements and milestone income, supporting business expansion.","jir_summary":"### Performance Overview\nNxera Pharma Co., Ltd. recorded revenue of 27,742 million yen for the cumulative third quarter period, with core operating profit of 9,818 million yen, operating profit of 3,175 million yen, and quarterly profit of 2,328 million yen. The company has turned from a large loss in the same quarter of the prior year to profitability. By product, sales of Pivratz\u00ae and Cubivic\u00ae remained solid, while revenue in the respiratory disease segment declined. R&D expenses decreased, and certain costs were reassessed, with structural reform expenses recorded. Full-year guidance is revenue of 33,800\u201348,800 million yen, core operating profit of 7,800\u201322,800 million yen, and operating profit of 700\u201315,700 million yen.\n\n### Outlook and Impact for Investors\nImportant license agreements and milestone income are expected to continue, and the company will continue to promote partnerships and in-house development leveraging the NxWave platform. From 2026 onward, the company aims to expand new partnerships and advance program phases; while monitoring factors such as foreign exchange and impairments, recognition of multiple milestone incomes could contribute to results. Although cash and cash equivalents are trending downward, improvement in cash generation is expected through portfolio expansion and partnership outcomes.","jir_financial_highlights":"Revenue: 27,742 (Increase of 5,894 YoY)\nCore Operating Profit: 9,818 (Turned from a loss of 986 YoY to a profit)\nOperating Profit: 3,175 (Turned from a loss of 5,907 YoY to a profit)\nQuarterly Profit: 2,328 (Turned from a loss of 4,809 YoY to a profit)\nCash and Cash Equivalents at Period End: 16,613 (Decreased from the end of the previous fiscal year)","jir_category":"","jir_hashtags":"#NxeraPharma, #Earnings, #NxWave, #PipelineExpansion","jir_key_figures":"Revenue: 27,742 million yen\nCore Operating Profit: 9,818 million yen\nOperating Profit: 3,175 million yen","jir_meta_title":"Nxera Pharma Co., Ltd. Third Quarter Financial Highlights\uff5cFiscal Year Ending December 2026","jir_meta_description":"Key points from Nxera Pharma Co., Ltd.'s third quarter financial summary for the fiscal year ending December 2026: revenue and profit trends, full-year guidance, and outlook on milestone income and license agreements.","jir_og_title":"Nxera Pharma Co., Ltd. Third Quarter Financial Highlights","jir_og_description":"Nxera Pharma Co., Ltd. reported revenue growth and a return to profitability in the third quarter. Full-year guidance is 33,800\u201348,800 million yen, with progress in milestone income under watch.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138896","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n